Is Elicio Therapeutics, Inc. (ELTX) a Buy, Sell, or Hold?
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$3.17 USD
$0.06 (1.93%)
- Volume
- 23.28K
- Average Volume
- 1.66M
- Market Capitalization
- $60.44M
- P/E Ratio
- -1.34
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $16.00
- Year Low
- $2.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.24
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Robert T. Connelly |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ELTX |
| CUSIP | 28657F103 |
| CIK | 0001601485 |
| Web | https://elicio.com |
| Phone | 857-209-0050 |
| Currency | USD |
| Employees | 33 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -9.98 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.24 |
| Quick Ratio | 2.24 |
| Cash Ratio | 2.07 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.11 |
| Price / Cash Flow | -1.57 |
| Price / Book | -40.17 |
Price Target and Rating
| Average Stock Price Forecast | $17.00 |
| High Stock Price Forecast | $17.00 |
| Low Stock Price Forecast | $17.00 |
| Forecast Upside/Downside | -81.35% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.58 |
| Trailing P/E Ratio | -1.34 |
| PEG Ratio | -0.02 |
| P/E Growth | -0.02 |
| Net Income | $-39.57M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -2748.16% |
| Return on Assets | -177.11% |
Financials Score
| AltmanZ Score | -18.81 |
| Piotroski Score | 2.00 |
| Working Capital | 8.97M |
| Total Assets | 22.69M |
| Ebit | -38.82M |
| Market Cap | 60.73M |
| Total Liabilities | 24.13M |
Poll Results
About Elicio Therapeutics, Inc. (NASDAQ:ELTX) Stock
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR ... T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
2026-07-09 17:18:00
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-07 17:28:00
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
2026-07-06 16:05:00
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the closing of its previously announced registered direct offering (the “Offering”) pursuant to a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock. The gross proceeds to the Company were approximately $15 million, before deducting placement agents' fees and other Offering expenses. Elicio intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, to primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and Elicio's pipeline and platform, as well as for working capital and general corporate purposes.
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
2026-07-02 00:25:00
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents' fees and other Offering expenses. The closing of the Offering is expected to occur on or about July 6, 2026, subject to the satisfaction of customary closing conditions. Elicio intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, to primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and Elicio's pipeline and platform, as well as for working capital and general corporate purposes.
2026-06-30 17:05:00
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-06-29 08:00:00
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution. “Inclusion of Elicio Therapeutics in the Russell 2000® and Russell 3000® Indexes is a meaningful milestone that reflects the growing recognition of the Company's progress,” said Robert Connelly, Chief Executive Officer of Elicio Therapeutics.
2026-06-25 15:01:00
LOS ANGELES--(BUSINESS WIRE)---- $ELTX--ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
2026-06-25 10:00:00
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Frequently Asked Questions
-
What is the current Elicio Therapeutics, Inc. (ELTX) stock price?
-
Elicio Therapeutics, Inc.(NASDAQ:ELTX) stock price is $3.17 in the last trading session. During the trading session, ELTX stock reached the peak price of $16 while $2.66 was the lowest point it dropped to. The percentage change in ELTX stock occurred in the recent session was 1.93% while the dollar amount for the price change in ELTX stock was $0.06.
-
ELTX's industry and sector of operation?
-
The NASDAQ listed ELTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ELTX?
-
Allen Richard Nissenson FACP | Founder & Independent Director
Darrell J. Irvine | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
Peter DeMuth | Chief Scientific Officer
Christopher Haqq | Executive Vice President, Head of Research & Development and Chief Medical Officer
Preetam Shah | Chief Strategy & Financial Officer and Treasurer -
How many employees does ELTX have?
-
Number of ELTX employees currently stands at 33. ELTX operates from 451 D Street, Boston, MA 02210, US.
-
Link for ELTX official website?
-
Official Website of ELTX is: https://elicio.com
-
How do I contact ELTX?
-
ELTX could be contacted at phone #857-209-0050 and can also be accessed through its website. ELTX operates from 451 D Street, Boston, MA 02210, US.
-
How many shares of ELTX are traded daily?
-
The average number of ELTX shares traded daily for last 3 months was 1.66M.
-
What is the market cap of ELTX currently?
-
The market value of ELTX currently stands at $60.44M with its latest stock price at $3.17